array(40) {
  [0]=>
  string(4) "9084"
  ["article_id"]=>
  string(4) "9084"
  [1]=>
  string(162) "Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01"
  ["article_title"]=>
  string(162) "Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01"
  [2]=>
  string(150) "IRVINE, Calif., Jan. 18, 2024.  PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune diso"
  ["short_description"]=>
  string(150) "IRVINE, Calif., Jan. 18, 2024.  PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune diso"
  [3]=>
  string(242) "IRVINE, Calif., Jan. 18, 2024.  PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or..."
  ["description"]=>
  string(242) "IRVINE, Calif., Jan. 18, 2024.  PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(145) "https://www.drugs.com/clinical_trials/complete-remission-cohort-1-first-patient-treated-relapsed-refractory-b-cell-acute-lymphoblastic-21280.html"
  ["blog_url"]=>
  string(145) "https://www.drugs.com/clinical_trials/complete-remission-cohort-1-first-patient-treated-relapsed-refractory-b-cell-acute-lymphoblastic-21280.html"
  [15]=>
  string(19) "2024-01-19 05:01:38"
  ["add_date"]=>
  string(19) "2024-01-19 05:01:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9085"
  ["article_id"]=>
  string(4) "9085"
  [1]=>
  string(115) "Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients"
  ["article_title"]=>
  string(115) "Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients"
  [2]=>
  string(150) "NEW YORK, Jan. 18, 2024. Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug"
  ["short_description"]=>
  string(150) "NEW YORK, Jan. 18, 2024. Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug"
  [3]=>
  string(244) "NEW YORK, Jan. 18, 2024. Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing..."
  ["description"]=>
  string(244) "NEW YORK, Jan. 18, 2024. Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(149) "https://www.drugs.com/clinical_trials/hoth-therapeutics-announces-received-fda-approval-expand-ht-001-clinical-trial-severely-ill-patients-21279.html"
  ["blog_url"]=>
  string(149) "https://www.drugs.com/clinical_trials/hoth-therapeutics-announces-received-fda-approval-expand-ht-001-clinical-trial-severely-ill-patients-21279.html"
  [15]=>
  string(19) "2024-01-19 05:01:14"
  ["add_date"]=>
  string(19) "2024-01-19 05:01:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9123"
  ["article_id"]=>
  string(4) "9123"
  [1]=>
  string(65) "Federal Judge Denies Coalition Protection From Anti-Kickback Laws"
  ["article_title"]=>
  string(65) "Federal Judge Denies Coalition Protection From Anti-Kickback Laws"
  [2]=>
  string(158) "&#nl        Brushing aside a pharmaceutical coalition’s First Amendment claims and upholding a 2023 advisory opinion, a federal judge has rejected a pl"
  ["short_description"]=>
  string(158) "&#nl        Brushing aside a pharmaceutical coalition’s First Amendment claims and upholding a 2023 advisory opinion, a federal judge has rejected a pl"
  [3]=>
  string(282) "&#nl        Brushing aside a pharmaceutical coalition’s First Amendment claims and upholding a 2023 advisory opinion, a federal judge has rejected a plan for a proposed cancer-drug price relief program, ruling that it runs afoul of the Anti Kick-Back Statute (AKS).&#nl      "
  ["description"]=>
  string(282) "&#nl        Brushing aside a pharmaceutical coalition’s First Amendment claims and upholding a 2023 advisory opinion, a federal judge has rejected a plan for a proposed cancer-drug price relief program, ruling that it runs afoul of the Anti Kick-Back Statute (AKS).&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(105) "https://www.fdanews.com/articles/213136-federal-judge-denies-coalition-protection-from-anti-kickback-laws"
  ["blog_url"]=>
  string(105) "https://www.fdanews.com/articles/213136-federal-judge-denies-coalition-protection-from-anti-kickback-laws"
  [15]=>
  string(19) "2024-01-19 03:55:22"
  ["add_date"]=>
  string(19) "2024-01-19 03:55:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:51"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9225"
  ["article_id"]=>
  string(4) "9225"
  [1]=>
  string(65) "Why digital equity is important to conducting better telemedicine"
  ["article_title"]=>
  string(65) "Why digital equity is important to conducting better telemedicine"
  [2]=>
  string(150) "Alexandra Hunter, virtual care consultant at Henry Ford Health, previews her HIMSS24 session, where she will explore ways in which Henry Ford and othe"
  ["short_description"]=>
  string(150) "Alexandra Hunter, virtual care consultant at Henry Ford Health, previews her HIMSS24 session, where she will explore ways in which Henry Ford and othe"
  [3]=>
  string(220) "Alexandra Hunter, virtual care consultant at Henry Ford Health, previews her HIMSS24 session, where she will explore ways in which Henry Ford and other health systems have addressed equity gaps and overcome barriers.&#nl"
  ["description"]=>
  string(220) "Alexandra Hunter, virtual care consultant at Henry Ford Health, previews her HIMSS24 session, where she will explore ways in which Henry Ford and other health systems have addressed equity gaps and overcome barriers.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(97) "https://www.healthcareitnews.com/news/why-digital-equity-important-conducting-better-telemedicine"
  ["blog_url"]=>
  string(97) "https://www.healthcareitnews.com/news/why-digital-equity-important-conducting-better-telemedicine"
  [15]=>
  string(19) "2024-01-19 00:43:16"
  ["add_date"]=>
  string(19) "2024-01-19 00:43:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9038"
  ["article_id"]=>
  string(4) "9038"
  [1]=>
  string(63) "Age-Adjusted Cancer Mortality Rates Decreased From 2000 to 2020"
  ["article_title"]=>
  string(63) "Age-Adjusted Cancer Mortality Rates Decreased From 2000 to 2020"
  [2]=>
  string(150) "THURSDAY, Jan. 18, 2024 -- From 2000 to 2020, U.S. age-adjusted cancer mortality rates decreased significantly, but racial and ethnic disparities pers"
  ["short_description"]=>
  string(150) "THURSDAY, Jan. 18, 2024 -- From 2000 to 2020, U.S. age-adjusted cancer mortality rates decreased significantly, but racial and ethnic disparities pers"
  [3]=>
  string(250) "THURSDAY, Jan. 18, 2024 -- From 2000 to 2020, U.S. age-adjusted cancer mortality rates decreased significantly, but racial and ethnic disparities persisted for certain cancers, according to a research letter published online Jan. 12 in JAMA Health..."
  ["description"]=>
  string(250) "THURSDAY, Jan. 18, 2024 -- From 2000 to 2020, U.S. age-adjusted cancer mortality rates decreased significantly, but racial and ethnic disparities persisted for certain cancers, according to a research letter published online Jan. 12 in JAMA Health..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(94) "https://www.drugs.com/news/age-adjusted-cancer-mortality-rates-decreased-2000-2020-117154.html"
  ["blog_url"]=>
  string(94) "https://www.drugs.com/news/age-adjusted-cancer-mortality-rates-decreased-2000-2020-117154.html"
  [15]=>
  string(19) "2024-01-19 00:01:57"
  ["add_date"]=>
  string(19) "2024-01-19 00:01:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9039"
  ["article_id"]=>
  string(4) "9039"
  [1]=>
  string(79) "Testosterone Treatment Does Not Cut Fracture Incidence in Men With Hypogonadism"
  ["article_title"]=>
  string(79) "Testosterone Treatment Does Not Cut Fracture Incidence in Men With Hypogonadism"
  [2]=>
  string(150) "THURSDAY, Jan. 18, 2024 -- Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypo"
  ["short_description"]=>
  string(150) "THURSDAY, Jan. 18, 2024 -- Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypo"
  [3]=>
  string(244) "THURSDAY, Jan. 18, 2024 -- Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a study published in the Jan. 18 issue of the New England Journal of..."
  ["description"]=>
  string(244) "THURSDAY, Jan. 18, 2024 -- Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a study published in the Jan. 18 issue of the New England Journal of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(100) "https://www.drugs.com/news/testosterone-does-not-cut-fracture-incidence-men-hypogonadism-117152.html"
  ["blog_url"]=>
  string(100) "https://www.drugs.com/news/testosterone-does-not-cut-fracture-incidence-men-hypogonadism-117152.html"
  [15]=>
  string(19) "2024-01-19 00:01:45"
  ["add_date"]=>
  string(19) "2024-01-19 00:01:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9040"
  ["article_id"]=>
  string(4) "9040"
  [1]=>
  string(55) "Recent Reduction Seen in Opioid Prescribing by Surgeons"
  ["article_title"]=>
  string(55) "Recent Reduction Seen in Opioid Prescribing by Surgeons"
  [2]=>
  string(150) "THURSDAY, Jan. 18, 2024 -- Opioid prescribing by surgeons decreased between 2013 and 2017, according to a study published online Jan. 16 in the J"
  ["short_description"]=>
  string(150) "THURSDAY, Jan. 18, 2024 -- Opioid prescribing by surgeons decreased between 2013 and 2017, according to a study published online Jan. 16 in the J"
  [3]=>
  string(254) "THURSDAY, Jan. 18, 2024 -- Opioid prescribing by surgeons decreased between 2013 and 2017, according to a study published online Jan. 16 in the Journal of the American College of Surgeons.&#nlApostolos Gaitanidis, M.D., from Massachusetts General..."
  ["description"]=>
  string(254) "THURSDAY, Jan. 18, 2024 -- Opioid prescribing by surgeons decreased between 2013 and 2017, according to a study published online Jan. 16 in the Journal of the American College of Surgeons.&#nlApostolos Gaitanidis, M.D., from Massachusetts General..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(76) "https://www.drugs.com/news/recent-reduction-seen-opioid-surgeons-117150.html"
  ["blog_url"]=>
  string(76) "https://www.drugs.com/news/recent-reduction-seen-opioid-surgeons-117150.html"
  [15]=>
  string(19) "2024-01-19 00:01:36"
  ["add_date"]=>
  string(19) "2024-01-19 00:01:36"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9305"
  ["article_id"]=>
  string(4) "9305"
  [1]=>
  string(86) "UK maintains status as an attractive destination for advanced therapy clinical trials "
  ["article_title"]=>
  string(86) "UK maintains status as an attractive destination for advanced therapy clinical trials "
  [2]=>
  string(150) "The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has reveale"
  ["short_description"]=>
  string(150) "The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has reveale"
  [3]=>
  string(312) "The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical trial accounting for 81% of trials in 2023 and 80% in 2022."
  ["description"]=>
  string(312) "The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical trial accounting for 81% of trials in 2023 and 80% in 2022."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(191) "https://www.biopharma-reporter.com/Article/2024/01/18/uk-maintains-status-as-an-attractive-destination-for-advanced-therapy-clinical-trials?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(191) "https://www.biopharma-reporter.com/Article/2024/01/18/uk-maintains-status-as-an-attractive-destination-for-advanced-therapy-clinical-trials?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-18 23:39:00"
  ["add_date"]=>
  string(19) "2024-01-18 23:39:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9185"
  ["article_id"]=>
  string(4) "9185"
  [1]=>
  string(57) "Mass finishing and shot blasting for medical applications"
  ["article_title"]=>
  string(57) "Mass finishing and shot blasting for medical applications"
  [2]=>
  string(156) "Colin Spellacy, head of sales, Rösler UK discusses how in the precision-driven realms of the medical industry, the roles of mass finishing and shot"
  ["short_description"]=>
  string(156) "Colin Spellacy, head of sales, Rösler UK discusses how in the precision-driven realms of the medical industry, the roles of mass finishing and shot"
  [3]=>
  string(200) "Colin Spellacy, head of sales, Rösler UK discusses how in the precision-driven realms of the medical industry, the roles of mass finishing and shot blasting technologies cannot be overstated."
  ["description"]=>
  string(200) "Colin Spellacy, head of sales, Rösler UK discusses how in the precision-driven realms of the medical industry, the roles of mass finishing and shot blasting technologies cannot be overstated."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(167) "https://www.medicalplasticsnews.com/medical-plastics-industry-insights/medical-plastics-3d-printing-insights/mass-finishing-and-shot-blasting-for-medical-applications/"
  ["blog_url"]=>
  string(167) "https://www.medicalplasticsnews.com/medical-plastics-industry-insights/medical-plastics-3d-printing-insights/mass-finishing-and-shot-blasting-for-medical-applications/"
  [15]=>
  string(19) "2024-01-18 23:37:11"
  ["add_date"]=>
  string(19) "2024-01-18 23:37:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:42"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9204"
  ["article_id"]=>
  string(4) "9204"
  [1]=>
  string(88) "Inceptua and Cycle partnership brings hope to patients at the end of the treatment road "
  ["article_title"]=>
  string(88) "Inceptua and Cycle partnership brings hope to patients at the end of the treatment road "
  [2]=>
  string(150) "Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare gen"
  ["short_description"]=>
  string(150) "Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare gen"
  [3]=>
  string(214) "Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise."
  ["description"]=>
  string(214) "Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(171) "https://www.outsourcing-pharma.com/Article/2024/01/18/Nitisinone-brought-to-rare-disease-patients-thanks-to-partnership?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(171) "https://www.outsourcing-pharma.com/Article/2024/01/18/Nitisinone-brought-to-rare-disease-patients-thanks-to-partnership?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-18 23:11:00"
  ["add_date"]=>
  string(19) "2024-01-18 23:11:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:49"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9304"
  ["article_id"]=>
  string(4) "9304"
  [1]=>
  string(89) "First patient dosed in Oxford BioTherapeutics’ trial for head and neck cancer drug"
  ["article_title"]=>
  string(89) "First patient dosed in Oxford BioTherapeutics’ trial for head and neck cancer drug"
  [2]=>
  string(150) "Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT07"
  ["short_description"]=>
  string(150) "Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT07"
  [3]=>
  string(222) "Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck."
  ["description"]=>
  string(222) "Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(187) "https://www.biopharma-reporter.com/Article/2024/01/18/first-patient-dosed-in-oxford-biotherapeutics-trial-for-head-and-neck-cancer-drug?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(187) "https://www.biopharma-reporter.com/Article/2024/01/18/first-patient-dosed-in-oxford-biotherapeutics-trial-for-head-and-neck-cancer-drug?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-18 23:00:00"
  ["add_date"]=>
  string(19) "2024-01-18 23:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9226"
  ["article_id"]=>
  string(4) "9226"
  [1]=>
  string(55) "NIH entity seeks proposals for advanced mobile hospital"
  ["article_title"]=>
  string(55) "NIH entity seeks proposals for advanced mobile hospital"
  [2]=>
  string(157) "ARPA-H is launching a program to deliver acute care in rural settings via a multipurpose delivery platform "that is as convenient as telehealth."&#nl"
  ["short_description"]=>
  string(157) "ARPA-H is launching a program to deliver acute care in rural settings via a multipurpose delivery platform "that is as convenient as telehealth."&#nl"
  [3]=>
  string(157) "ARPA-H is launching a program to deliver acute care in rural settings via a multipurpose delivery platform "that is as convenient as telehealth."&#nl"
  ["description"]=>
  string(157) "ARPA-H is launching a program to deliver acute care in rural settings via a multipurpose delivery platform "that is as convenient as telehealth."&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(82) "https://www.healthcareitnews.com/news/nih-seeks-proposals-advanced-mobile-hospital"
  ["blog_url"]=>
  string(82) "https://www.healthcareitnews.com/news/nih-seeks-proposals-advanced-mobile-hospital"
  [15]=>
  string(19) "2024-01-18 22:31:37"
  ["add_date"]=>
  string(19) "2024-01-18 22:31:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}